RxDoctor Payments Data

Lesley Pipkins, PA

Physician Assistant · Tulsa, OKNPI 1417914870

Payments from drug & device makers

$1,614in general payments, 2019–2025

Across 77 payments — averaging $20.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$238
  • AstraZeneca$186
  • Lilly USA, LLC$160
  • Novo Nordisk$156
  • Pfizer$110
  • Dexcom, Inc.$92
  • plus $672 from 15 others

What the payments were for

  • Food & beverage$1,614100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,614 in reported general payments places this provider in the 75th percentile of 1,491 physician assistant providers in Oklahoma.

See all physician assistant providers in Oklahoma

Medicare billing

Part B allowed, 2024
$30,418
Medicare patients
187
Services billed
594

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide18$17,802
JardianceEmpagliflozin20$17,619
MounjaroTirzepatide12$14,138
EliquisApixaban14$12,522
FarxigaDapagliflozin Propanediol13$11,653
MyrbetriqMirabegron16$7,213
Atorvastatin Calcium94$2,108
Lantus SolostarInsulin Glargine,hum.Rec.Anlog20$1,592
Rosuvastatin Calcium52$1,500
Pantoprazole Sodium58$898
Losartan Potassium57$867
Omeprazole58$858
Albuterol Sulfate HfaAlbuterol Sulfate38$846
Potassium Chloride28$759
Bupropion XlBupropion Hcl17$745

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$156$17,80218 claims
Boehringer IngelheimJardiance$50$17,61920 claims
Lilly USA, LLCMounjaro$160$14,13812 claims
PfizerEliquis$110$12,52214 claims
AstraZenecaFarxiga$186$11,65313 claims
Astellas Pharma US IncMyrbetriq$78$7,21316 claims
Amneal Pharmaceuticals LLCLevothyroxine Sodium$44$31955 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 1,491 physician assistant providers in Oklahoma.

Other physician assistant in Tulsa

See the full list for Oklahoma

Where these figures come from

Is this you, or does something look wrong? →